Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 J&J's 3Q Revenue up 5% | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

J&J’s 3Q Revenue up 5%

Growth driven by Darzalex, Erleada, Carvykti, Tremfya, Spravato and Opsumit, offset by declines for Stelara and Simponi.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson
3Q Revenues: $22.5 billion (+5%)
3Q Earnings: $2.7 billion (-38%)
YTD Revenues: $42.6 billion (+4%)
YTD Earnings: $10.6 billion (-66%)
Comments: Growth in the quarter was driven by Darzalex, up 21% to $3.0 billion; Erleada, up 25% to $790 million; other oncology, with sales of $250 million; and Carvykti in oncology, up 88% to $286 million; Tremfya in immunology, up 13% to $1.0 billion; Spravato in neuroscience, up 55% to $284 million, and Opsumit in pulmonary hypertension, up 17% to $571 million. Growth was offset by declines for Stelara, down 7% to $2.7 billion and Simponi down 18% to $516 million. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters